Log in or register to see all Alerts
New HTA Decisions in England
October 2020
Drug name
PIQRAY® (alpelisib)
Company
Novartis
Decision date
//
Therapeutic area
Cancer
Therapeutic sub area
Breast cancer
Decision
Not recommended
Indication
Alpelisib (Piqray) with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on alpelisib (Piqray) with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.